Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Avalyn Pharma Inc. - common stock (NQ:AVLN)

26.11 -1.14 (-4.20%)
Delayed Quote Updated: 3:49 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avalyn Pharma Inc. - common stock

News headline image
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs 
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Company expects to report topline 12-month clinical results in the second half of 2027 
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead ↗
Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies... 
Via MarketBeat
Topics Initial Public Offering
News headline image
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in the Jefferies Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.